PMID- 26674626
OWN - NLM
STAT- MEDLINE
DCOM- 20160113
LR  - 20181202
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 54
IP  - 8
DP  - 2015 Aug
TI  - [The efficacy and prognostic predictors of different treatment courses with 
      pegylated interferon alpha-2a and ribavirin combination in recurrent chronic 
      hepatitis C patients].
PG  - 699-704
AB  - OBJECTIVE: To study the efficacy and outcome predictors of combined re-treatment 
      with pegylated interferon (Peg-IFN) alpha-2a and ribavirin in recurrent chronic 
      hepatitis C (CHC) patients. METHODS: A multicenter, prospective, randomized trial 
      was designed. A total of 125 recurrent CHC patients were recruited in 16 clinical 
      centers and randomly assigned into two groups: one was Peg-IFNalpha-2a combined with 
      ribavirin for 48 weeks (group A) and the other the same combination for 72 weeks 
      (group B). HCV RNA levels in patients' serum were detected at baseline, week 4, 
      12, 24, 48, 72 (group B) after treatment initiation, and 24 weeks after 
      treatment. RESULTS: Of all the 90 patients who completed treatment and 24 weeks 
      follow-up, 80.0% achieved sustained virological response (SVR) yet 12.2% 
      relapsed. There was no significant difference between two groups. The SVR rate in 
      patients previously treated with interferon alone was higher than that in 
      patients with interferon plus ribavirin (92.6% vs 74.6%), but the difference was 
      of no statistical significance (P = 0.05). Moreover, patients previously treated 
      with common interferon (c-IFN) showed a higher SVR rate than patients with 
      Peg-IFN (84.7% vs 71.0%, P > 0.05). The positive predictive value (PV) of rapid 
      virological response (RVR) and complete early virological response for SVR was 
      92.3% and 86.4% respectively, and the negative PV of RVR, early virological 
      response and delayed virological response for SVR was 36.8%, 66.7% and 100.0% 
      respectively. Overall, 62.1% patients reported adverse events (AEs) and 1.6% 
      patients were severe AEs. CONCLUSIONS: A high SVR rate has been achieved in 
      recurrent CHC patients who were retreated with Peg-IFNalpha-2a and ribavirin for 48 
      weeks. Better SVR cannot be achieved in spite of a prolonged course of 72 weeks. 
      Early virological response at week 12 was the most important predictor for SVR.
FAU - Rao, Huiying
AU  - Rao H
FAU - Yang, Ruifeng
AU  - Yang R
FAU - Shang, Jia
AU  - Shang J
FAU - Xu, Xiaoyuan
AU  - Xu X
FAU - Chen, Xinyue
AU  - Chen X
FAU - Dou, Xiaoguang
AU  - Dou X
FAU - Feng, Yinong
AU  - Feng Y
FAU - Gao, Zhiliang
AU  - Gao Z
FAU - Xie, Qing
AU  - Xie Q
FAU - Li, Jun
AU  - Li J
FAU - You, Hong
AU  - You H
FAU - Chen, Guofeng
AU  - Chen G
FAU - Niu, Junqi
AU  - Niu J
FAU - Gong, Guozhong
AU  - Gong G
FAU - Hou, Jinlin
AU  - Hou J
FAU - Chen, Hong
AU  - Chen H
FAU - Zhang, Dazhi
AU  - Zhang D
FAU - Wei, Lai
AU  - Wei L
AD  - Peking University People's Hospital, Peking University Hepatology Institute, 
      Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, 
      Beijing 100044, China; Email: weilai@pkuph.edu.cn.
LA  - chi
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Combined Modality Therapy
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/*drug effects
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Polyethylene Glycols/*therapeutic use
MH  - Prognosis
MH  - Prospective Studies
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/*therapeutic use
MH  - Treatment Outcome
EDAT- 2015/12/18 06:00
MHDA- 2016/01/14 06:00
CRDT- 2015/12/18 06:00
PHST- 2015/12/18 06:00 [entrez]
PHST- 2015/12/18 06:00 [pubmed]
PHST- 2016/01/14 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2015 Aug;54(8):699-704.